Navigation Links
HIV research findings made possible by a test developed at CU School of Pharmacy
Date:7/28/2014

HIV research findings made possible by a test developed at University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences (CU School of Pharmacy) AURORA, Colo (July 28, 2014) An influential new test, discovered and developed in the Colorado Antiviral Pharmacology Laboratory at the CU School of Pharmacy, helps monitor the effectiveness of the HIV prevention drug called Truvada (a combination of tenofovir/emtricitabine), which is taken once daily to prevent HIV infection.

A study presented during the AIDS 2014 Conference and published in Lancet Infectious Diseases on the efficacy and safety of prophylactic use of Truvada to protect against HIV infection relied on a test developed at the school. The test measures the amount of tenofovir-diphosphate (a metabolite of tenofovir) in red blood cells, using a dried blood spot. Because of a long half-life, high amounts of the metabolite in the dried blood spot correspond with consistent dosing of Truvada and low amounts correspond with inconsistent dosing. The new test was used in the iPrEx open label extension study (iPrEx OLE) published in Lancet Infectious Diseases to estimate patterns of tablet use during the study. The new test showed a continuous gradient of increasing efficacy (fewer HIV infections) with increasing drug concentrations. Dr. Peter Anderson, whose laboratory developed the test, said, "Participants in the study who had tablet use consistent with 4 or more tablets per week, as determined by the new test, had no HIV infections (estimated 100% efficacy)."

The US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recently issued guidelines recommending the use of antiretroviral medicines as an additional method of preventing HIV infection. "Findings from iPrEX OLE are particularly important in relation to emerging guidelines recommending widespread use of PrEP," said Protocol Chair Robert Grant, MD, PGH of the Gladstone Institutes, the University of California at San Francisco and the San Francisco AIDS Foundation.


'/>"/>

Contact: Dana Brandorff
dana.brandorff@ucdenver.edu
303-724-4618
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Researchers identify potential biomarker for AD
2. Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com
3. Online information most cost-effective means of increasing MMR uptake, research finds
4. Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld
5. Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com
6. Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com
7. Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld
8. Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org
9. 2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com
10. Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com
11. Young earns GSAs 2014 Doris Schwartz Gerontological Nursing Research Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... 17, 2019 , ... Caravan Health is seeking ... the country, the company announced today. High-performing community health systems and providers can ... cost efficiency. This opportunity is open to those new to value-based Medicare payment ...
(Date:9/17/2019)... PASO ROBLES, Calif. (PRWEB) , ... September 17, ... ... Pismo Beach , CA, recently announced that he has been certified by the ... Botox in dentistry is used to correct a wide range of orofacial conditions ...
(Date:9/17/2019)... BOSTON (PRWEB) , ... September 17, 2019 , ... ... Participation (CISCRP) is pleased to announce the release of the third edition of ... a comprehensive, easy-to-read guide for patients, caregivers and families to navigate the clinical ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... detection and treatment of infectious diseases at its annual Congress (WMIC) recently ... detection of residual HIV infected cell persistence and the development of pathogen-specific ...
(Date:9/11/2019)... ... September 12, 2019 , ... “Heart Seizures”: a useful ... coronary artery disease as he hopes to prevent anyone from having it and to ... author John Saltwick, a writer who was diagnosed with coronary artery disease. Predicted to ...
Breaking Medicine News(10 mins):
(Date:9/18/2019)... ... September 18, 2019 , ... NDA Partners Chairman ... well-respected preclinical drug development expert with a focus in the cardiovascular and metabolic ... to joining NDA Partners, Dr. Hoffmann served as Executive Director of Preclinical Safety ...
(Date:9/17/2019)... New Zealand (PRWEB) , ... September 17, 2019 , ... ... in in Fast Company’s 2019 Innovation by Design Awards Students category. , It was ... at the Auckland Bioengineering Institute. , Muss-Bits is comprised of two parts. A “sensor ...
(Date:9/17/2019)... ... 2019 , ... Scientists writing in a 2017 issue of ... progressive destruction of joint cartilage in osteoarthritis are “on the close horizon.” ... orthopedic surgeon Alejandro Badia, MD , founder and chief medical officer of ...
Breaking Medicine Technology: